Overview
Pharma.AI platform spanning PandaOmics target discovery, Chemistry42 generative chemistry, and clinical development tools — plus an internal pipeline of AI-originated drug candidates across fibrosis, oncology, and immunology.
Product and company
Insilico Medicine — Biotechnology is a verified product offering linked to the Brel Digital company profile for Insilico Medicine.
Use cases
Pharma.AI platform spanning PandaOmics target discovery, Chemistry42 generative chemistry, and clinical development tools — plus an internal pipeline of AI-originated drug candidates across fibrosis, oncology, and immunology.
Target customer
Pharmaceutical partners licensing AI platforms, biotech collaborators co-developing assets, and the clinical research community evaluating AI-native drug candidates in Phase II and III trials.
Technologies
Primary technologies assigned from the linked company profile: Clinical Documentation, Deep Learning, Generative AI, Healthcare Analytics, Machine Learning, Predictive Analytics.
Sources and references
- Official product / company source: https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr
- Supporting source: https://insilico.com/management
Product facts are limited to information already verified on the linked Brel company profile and its cited official URLs. No speculative capabilities are added.
Last reviewed
This product profile was last reviewed on 2026-07-14.
Correction request
If this product record is inaccurate or outdated, submit a correction through Brel Digital’s Corrections Policy.
Features and capabilities
- Pharma.AI platform spanning PandaOmics target discovery, Chemistry42 generative chemistry, and clinical development tools — plus an internal pipeline of AI-originated drug candidates across fibrosis, oncology, and immunology.
Extracted from the linked company product description already verified on Brel. No capabilities were invented.